company background image
AVCN

Avicanna TSX:AVCN Stock Report

Last Price

CA$0.24

Market Cap

CA$12.8m

7D

4.3%

1Y

n/a

Updated

26 Jun, 2022

Data

Company Financials
AVCN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AVCN Stock Overview

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide.

Avicanna Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Avicanna
Historical stock prices
Current Share PriceCA$0.24
52 Week HighCA$1.01
52 Week LowCA$0.16
Beta1.89
1 Month Change-33.33%
3 Month Change-39.24%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-96.15%

Recent News & Updates

Shareholder Returns

AVCNCA PharmaceuticalsCA Market
7D4.3%-0.3%0.3%
1Yn/a-70.9%-4.0%

Return vs Industry: Insufficient data to determine how AVCN performed against the Canadian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how AVCN performed against the Canadian Market.

Price Volatility

Is AVCN's price volatile compared to industry and market?
AVCN volatility
AVCN Average Weekly Movement21.0%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement10.0%
10% most volatile stocks in CA Market17.3%
10% least volatile stocks in CA Market4.4%

Stable Share Price: AVCN is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: AVCN's weekly volatility has increased from 15% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016124Aras Azadianhttps://www.avicanna.com

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments.

Avicanna Fundamentals Summary

How do Avicanna's earnings and revenue compare to its market cap?
AVCN fundamental statistics
Market CapCA$12.82m
Earnings (TTM)-CA$14.61m
Revenue (TTM)CA$4.04m

3.2x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVCN income statement (TTM)
RevenueCA$4.04m
Cost of Revenue-CA$192.62k
Gross ProfitCA$4.23m
Other ExpensesCA$18.84m
Earnings-CA$14.61m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.27
Gross Margin104.77%
Net Profit Margin-362.02%
Debt/Equity Ratio23.4%

How did AVCN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is AVCN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AVCN?

Other financial metrics that can be useful for relative valuation.

AVCN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5x
Enterprise Value/EBITDA-2.3x
PEG Ration/a

Price to Sales Ratio vs Peers

How does AVCN's PS Ratio compare to its peers?

AVCN PS Ratio vs Peers
The above table shows the PS ratio for AVCN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average2.5x

Price-To-Sales vs Peers: AVCN is expensive based on its Price-To-Sales Ratio (3.2x) compared to the peer average (2.5x).


Price to Earnings Ratio vs Industry

How does AVCN's PE Ratio compare vs other companies in the Canadian Pharmaceuticals Industry?

Price-To-Sales vs Industry: AVCN is expensive based on its Price-To-Sales Ratio (3.2x) compared to the Canadian Pharmaceuticals industry average (2x)


Price to Sales Ratio vs Fair Ratio

What is AVCN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AVCN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AVCN's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of AVCN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AVCN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AVCN's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AVCN's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Avicanna forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


72.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Avicanna has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Avicanna's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Avicanna competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Avicanna performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-27.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AVCN is currently unprofitable.

Growing Profit Margin: AVCN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AVCN is unprofitable, and losses have increased over the past 5 years at a rate of 27.9% per year.

Accelerating Growth: Unable to compare AVCN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVCN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (118.1%).


Return on Equity

High ROE: AVCN has a negative Return on Equity (-140.46%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Avicanna's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AVCN's short term assets (CA$10.9M) do not cover its short term liabilities (CA$12.8M).

Long Term Liabilities: AVCN's short term assets (CA$10.9M) exceed its long term liabilities (CA$3.1M).


Debt to Equity History and Analysis

Debt Level: AVCN's net debt to equity ratio (8.3%) is considered satisfactory.

Reducing Debt: AVCN's debt to equity ratio has reduced from 44.1% to 23.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVCN has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: AVCN is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Dividend

What is Avicanna current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVCN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVCN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVCN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVCN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AVCN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Aras Azadian

6.42yrs

Tenure

CA$358,101

Compensation

Mr. Aras Azadian, Msc Management, B.Econ, MBA, is a Co-Founder of Avicanna Inc. He serves as Chief Executive Officer and Director since November 25, 2016 of Avicanna Inc. and served as its Chairman until O...


CEO Compensation Analysis

Compensation vs Market: Aras's total compensation ($USD277.23K) is above average for companies of similar size in the Canadian market ($USD175.18K).

Compensation vs Earnings: Aras's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AVCN's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: AVCN's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AVCN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.8%.


Top Shareholders

Company Information

Avicanna Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Avicanna Inc.
  • Ticker: AVCN
  • Exchange: TSX
  • Founded: 2016
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$12.819m
  • Shares outstanding: 53.41m
  • Website: https://www.avicanna.com

Number of Employees


Location

  • Avicanna Inc.
  • 480 University Avenue
  • Suite 1502
  • Toronto
  • Ontario
  • M5G 1V2
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.